Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-005983
Filing Date
2025-08-12
Accepted
2025-08-12 17:00:57
Documents
44
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUN 2025 xenetic_i10q-063025.htm   iXBRL 10-Q 508527
2 THIRD AMENDMENT TO RESEARCH FUNDING AND OPTION AGREEMENT xenetic_ex1001.htm EX-10.1 74635
3 CERTIFICATION xenetic_ex3101.htm EX-31.1 10167
4 CERTIFICATION xenetic_ex3102.htm EX-31.2 10184
5 CERTIFICATION xenetic_ex3201.htm EX-32.1 4208
  Complete submission text file 0001683168-25-005983.txt   2739352

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE xbio-20250630.xsd EX-101.SCH 17814
7 XBRL CALCULATION FILE xbio-20250630_cal.xml EX-101.CAL 24532
8 XBRL DEFINITION FILE xbio-20250630_def.xml EX-101.DEF 75389
9 XBRL LABEL FILE xbio-20250630_lab.xml EX-101.LAB 197111
10 XBRL PRESENTATION FILE xbio-20250630_pre.xml EX-101.PRE 156809
46 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_i10q-063025_htm.xml XML 286563
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37937 | Film No.: 251207702
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)